Cell Therapy Market (By Use Type: Clinical use, Research use; By Therapy Type: Autologous Therapies, Allogenic Therapies; By End User: Hospitals & Clinics, Academic & Research Institutes; By Technology) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022 – 2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cell Therapy Market 

5.1. COVID-19 Landscape: Cell Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cell Therapy Market, By Use Type

8.1. Cell Therapy Market, by Use Type, 2022-2030

8.1.1. Clinical use

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Research use

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Cell Therapy Market, By Therapy Type

9.1. Cell Therapy Market, by Therapy Type, 2022-2030

9.1.1. Autologous Therapies

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Allogenic Therapies

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Cell Therapy Market, By End User 

10.1. Cell Therapy Market, by End User, 2022-2030

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Diagnostic centers

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Clinics

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Research institutes

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Regenerative medicine centers

10.1.5.1. Market Revenue and Forecast (2017-2030)

10.1.6. Others

10.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Cell Therapy Market, By Technology 

11.1. Cell Therapy Market, by Technology, 2022-2030

11.1.1. Viral Vector Technology

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Genome Editing Technology

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Somatic Cell Technology

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Cell Immortalization Technology

11.1.4.1. Market Revenue and Forecast (2017-2030)

11.1.5. Cell Plasticity Technology

11.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Cell Therapy Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.1.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.1.3. Market Revenue and Forecast, by End User (2017-2030)

12.1.4. Market Revenue and Forecast, by Technology (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.1.5.3. Market Revenue and Forecast, by End User (2017-2030)

12.1.5.4. Market Revenue and Forecast, by Technology (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.1.6.3. Market Revenue and Forecast, by End User (2017-2030)

12.1.6.4. Market Revenue and Forecast, by Technology (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.2.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.3. Market Revenue and Forecast, by End User (2017-2030)

12.2.4. Market Revenue and Forecast, by Technology (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.5.3. Market Revenue and Forecast, by End User (2017-2030)

12.2.5.4. Market Revenue and Forecast, by Technology (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.6.3. Market Revenue and Forecast, by End User (2017-2030)

12.2.6.4. Market Revenue and Forecast, by Technology (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.7.3. Market Revenue and Forecast, by End User (2017-2030)

12.2.7.4. Market Revenue and Forecast, by Technology (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.8.3. Market Revenue and Forecast, by End User (2017-2030)

12.2.8.4. Market Revenue and Forecast, by Technology (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.3.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.3. Market Revenue and Forecast, by End User (2017-2030)

12.3.4. Market Revenue and Forecast, by Technology (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.5.3. Market Revenue and Forecast, by End User (2017-2030)

12.3.5.4. Market Revenue and Forecast, by Technology (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.6.3. Market Revenue and Forecast, by End User (2017-2030)

12.3.6.4. Market Revenue and Forecast, by Technology (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.7.3. Market Revenue and Forecast, by End User (2017-2030)

12.3.7.4. Market Revenue and Forecast, by Technology (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.8.3. Market Revenue and Forecast, by End User (2017-2030)

12.3.8.4. Market Revenue and Forecast, by Technology (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.4.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.3. Market Revenue and Forecast, by End User (2017-2030)

12.4.4. Market Revenue and Forecast, by Technology (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.5.3. Market Revenue and Forecast, by End User (2017-2030)

12.4.5.4. Market Revenue and Forecast, by Technology (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.6.3. Market Revenue and Forecast, by End User (2017-2030)

12.4.6.4. Market Revenue and Forecast, by Technology (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.7.3. Market Revenue and Forecast, by End User (2017-2030)

12.4.7.4. Market Revenue and Forecast, by Technology (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.8.3. Market Revenue and Forecast, by End User (2017-2030)

12.4.8.4. Market Revenue and Forecast, by Technology (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.5.3. Market Revenue and Forecast, by End User (2017-2030)

12.5.4. Market Revenue and Forecast, by Technology (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.5.5.3. Market Revenue and Forecast, by End User (2017-2030)

12.5.5.4. Market Revenue and Forecast, by Technology (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.5.6.3. Market Revenue and Forecast, by End User (2017-2030)

12.5.6.4. Market Revenue and Forecast, by Technology (2017-2030)

Chapter 13. Company Profiles

13.1. Kolon TissueGene Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. JCR Pharmaceuticals Co. Ltd

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Castle Creek Biosciences Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Anterogen Co. Ltd

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. The Future of Biotechnology

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Celgene Corporation

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Tameika Cell Technologies Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Cells for Cells

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. MEDIPOST

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. NuVasive Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

PROCEED TO BUY

   USD 4500
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample